MEIP - MEI Pharma jumps 10% on promising zandelisib data in follicular lymphoma

MEI Pharma (NASDAQ:MEIP) and Kyowa Kirin (OTCPK:KYKOF) gains 10.2% premarket after announcing that the Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate (95% CI=59.8, 79.5) in the primary efficacy population (n=91). In addition, 35.2% of patients achieved a complete response. The data are currently insufficiently mature to accurately estimate duration of response. In line with previously reported data from the Phase 1B study, zandelisib was generally well tolerated. 9.9% of patients discontinued therapy due to a drug related adverse event. MEI will host an investor and analyst webcast today, at 8:00 AM ET to review the TIDAL phase 2 study data and to provide a corporate overview. Earlier this month, the FDA granted Orphan Drug designation to zandelisib.

For further details see:

MEI Pharma jumps 10% on promising zandelisib data in follicular lymphoma